Dexamethasone Suppression Tests in Graves' Disease [Abridged]

I C Gilliland et al. Proc R Soc Med. 1962 Feb.

. 1962 Feb;55(2):130-1.

doi: 10.1177/003591576205500207.

No abstract available

Similar articles

Relationship among thyrotropin (TSH), thyroid stimulating immunoglobulins, and results of triiodothyronine (T3) suppression test in patients with Graves' disease.
Horimoto M, Nishikawa M, Uno C, Yoshikawa N, Taniguchi N, Inada M. Horimoto M, et al. Endocrinol Jpn. 1988 Dec;35(6):841-8. doi: 10.1507/endocrj1954.35.841. Endocrinol Jpn. 1988. PMID: 2471633
Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease.
Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Wiersinga WM, et al. J Endocrinol Invest. 1988 Sep;11(8):615-9. doi: 10.1007/BF03350193. J Endocrinol Invest. 1988. PMID: 2907524
Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3).
Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Chopra IJ, et al. J Clin Endocrinol Metab. 1975 Nov;41(5):911-20. doi: 10.1210/jcem-41-5-911. J Clin Endocrinol Metab. 1975. PMID: 1242390
Graves' disease in children.
Léger J, Oliver I, Rodrigue D, Lambert AS, Coutant R. Léger J, et al. Ann Endocrinol (Paris). 2018 Dec;79(6):647-655. doi: 10.1016/j.ando.2018.08.001. Epub 2018 Aug 16. Ann Endocrinol (Paris). 2018. PMID: 30180972 Review.
Personalised immunomodulating treatments for Graves' disease: fact or fiction?
Struja TM, Kutz A, Fischli S, Meier C, Müller B, Schütz P. Struja TM, et al. Swiss Med Wkly. 2017 Aug 3;147:w14476. doi: 10.4414/smw.2017.14476. eCollection 2017. Swiss Med Wkly. 2017. PMID: 28804863 Review.